Myelodysplastic Syndromes | Topics

FDA Grants Breakthrough Therapy Designation to Magrolimab for Treatment of MDS
September 16, 2020

The FDA granted breakthrough therapy designation to magrolimab for the treatment of newly diagnosed myelodysplastic syndrome.

Phase 3 INSPIRE Study Fails to Meet Primary End Point of Improved Survival
August 24, 2020

The study evaluated the efficacy and safety of IV rigosertib in patients with high-risk MDS who had progressed on, failed to respond to, or relapsed after previous treatment with an HMA within 9 cycles over the course of 1 year after initiation of HMA treatment.

FDA Grants Breakthrough Therapy Designation for Pevonedistat to Treat Higher-Risk MDS
July 30, 2020

Takeda Pharmaceutical Company Limited announced the FDA granted pevonedistat, its investigation NEDD8-activating enzyme inhibitor, breakthrough therapy designation to treat patients with higher-risk myelodysplastic syndrome.